Improving the diagnosis and treatment of atypical myeloproliferative neoplasms
Atypical myeloproliferative neoplasms (aMPNs) are a group of rare blood cancers that include chronic myelomonocytic leukaemia (CMML), atypical chronic myeloid leukaemia (aCML), systemic mastocytosis and chronic eosinophilia. Because they are so biologically diverse, it’s very hard for doctors to predict how aMPNs will behave in terms of progression and response to treatment. They also generally have a poor outlook and current treatments often don’t work that well.
Professor Nick Cross and his team want to understand which genetic errors can lead to aMPNs and how these errors might be targeted for treatment. They are also looking for genes that make people more likely to have aMPNs and which could be passed on to children.
If successful, this research should improve our knowledge about the genes involved in this rare group of diseases, which will help improve how we diagnose and treat aMPNs.